The FDA on May 1, 2020 approved DARZALEX FASPRO® for adult patients with newly diagnosed or Relapsed/Refractory Multiple Myeloma. This new product allows for subcutaneous dosing of Daratumumab. DARZALEX FASPRO® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
